• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ProKidney Corp. - Class A Ordinary Shares (NQ: PROK )

    1.695 -0.455 (-21.16%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ProKidney Corp. - Class A Ordinary Shares

    < Previous 1 2 3 4 Next >
    ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
    From ProKidney
    Via GlobeNewswire
    PROK Stock Earnings: ProKidney Beats EPS for Q2 2024
    PROK stock results show that ProKidney beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    PROK Stock Earnings: ProKidney Reported Results for Q4 2023
    ProKidney just reported results for the fourth quarter of 2023. 
    Via InvestorPlace
    PROK Stock Earnings: ProKidney Beats EPS for Q1 2024
    PROK stock results show that ProKidney beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    ProKidney to Participate in the UBS Virtual Organ Restoration Day
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
    From ProKidney
    Via GlobeNewswire
    Over $30M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
    From ProKidney
    Via GlobeNewswire
    Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time to start the day with a breakdown of the biggest pre-market stock movers worth checking out on Tuesday morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
    From ProKidney
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! 
    Via InvestorPlace
    ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in the Jefferies Global Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
    From ProKidney
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    ProKidney Reports Business Updates and First Quarter 2024 Financial Results
    From ProKidney
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.